tirzepatide dual agonist is a first-in-class targeting both GIP and GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control 1 and GIP therapy Survodutide vs Tirzepatide: Dual GLP-1/GIP
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13



























